Sylvester Comprehensive Cancer Center (Main)

University of Miami Health System

Miami, FL

Sorting 11 by

Accepting patients

ACCESS

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (ACCESS)
Learn more
  • Allogeneic Stem Cell Transplant
  • Pre-Transplant
  • Phase 2

Accepting patients

R289

Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)
Learn more
  • IRAK 1 Inhibitor
  • IRAK 4 Inhibitor
  • Phase 1/2

Accepting patients

SX-682

A Phase 1, Open-Label, Dose-Escalation With Expansion Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
Learn more
  • CXCR1 Inhibitor
  • CXCR2 Inhibitor
  • Phase 1
  • Has results

Accepting patients

NEROFE

An Open-Label Phase 1b Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
Learn more
  • Phase 1

Accepting patients

Luspatercept and Lenalidomide (L2)

A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
Learn more
  • Erythroid Maturation Agent (EMA)
  • Immunomodulatory Drug
  • Red Blood Cell Stimulant
  • Phase 1/2

Accepting patients

Mismatched Related vs. Matched Unrelated Donor

A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) Versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Learn more
  • Allogeneic Stem Cell Transplant
  • Monoclonal Antibody
  • Phase 3

Accepting patients

KER-050

A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Learn more
  • Growth Factor
  • Phase 2
  • Has results

Accepting patients

LIMBER

A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Learn more
  • BET Inhibitor
  • JAK1 Inhibitor
  • JAK2 Inhibitor
  • Phase 1

Accepting patients

OPTIMIZE

A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Learn more
  • Allogeneic Stem Cell Transplant
  • Phase 2

Accepting patients

Music Therapy

Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation
Learn more